CY1119513T1 - Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης - Google Patents
Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσηςInfo
- Publication number
- CY1119513T1 CY1119513T1 CY20171100709T CY171100709T CY1119513T1 CY 1119513 T1 CY1119513 T1 CY 1119513T1 CY 20171100709 T CY20171100709 T CY 20171100709T CY 171100709 T CY171100709 T CY 171100709T CY 1119513 T1 CY1119513 T1 CY 1119513T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- treatment
- diagnosis
- recommendations
- secondary self
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
Abstract
Η εφεύρεση παρέχει μεθόδους διάγνωσης ασθενών με πολλαπλή σκλήρυνση (MS), συμπεριλαμβανομένων μεθόδων ταυτοποίησης ασθενών με πολλαπλή σκλήρυνση, οι οποίοι διατρέχουν αυξημένο κίνδυνο εμφάνισης δευτερογενούς αυτοάνοσης νόσου μετά από μείωση των λεμφοκυττάρων, που προκαλείται, π.χ., από αγωγή με αντίσωμα αντι-CD52. Επίσης, περιλαμβάνονται μέθοδοι επιλογής θεραπευτικών σχημάτων για ασθενείς με MS και αντιδραστήρια χρήσιμα στις παραπάνω μεθόδους.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19565808P | 2008-10-08 | 2008-10-08 | |
US19718708P | 2008-10-24 | 2008-10-24 | |
US19863108P | 2008-11-07 | 2008-11-07 | |
PCT/IB2009/007327 WO2010041149A2 (en) | 2008-10-08 | 2009-10-08 | Methods and compositions for diagnosis and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119513T1 true CY1119513T1 (el) | 2018-03-07 |
Family
ID=42061141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100709T CY1119513T1 (el) | 2008-10-08 | 2017-07-04 | Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης |
Country Status (22)
Country | Link |
---|---|
US (4) | US20110229470A1 (el) |
EP (2) | EP3241910B1 (el) |
JP (2) | JP5856481B2 (el) |
KR (2) | KR101682730B1 (el) |
CN (1) | CN102245783B (el) |
AU (1) | AU2009302117B2 (el) |
BR (1) | BRPI0920546B1 (el) |
CA (1) | CA2740077A1 (el) |
CY (1) | CY1119513T1 (el) |
DK (1) | DK2344677T3 (el) |
ES (2) | ES2784830T3 (el) |
HK (1) | HK1246364A1 (el) |
HR (1) | HRP20171023T1 (el) |
HU (1) | HUE035208T2 (el) |
IL (1) | IL212069A (el) |
LT (1) | LT2344677T (el) |
MX (1) | MX336835B (el) |
PL (2) | PL2344677T3 (el) |
PT (2) | PT3241910T (el) |
RU (1) | RU2563521C2 (el) |
SI (1) | SI2344677T1 (el) |
WO (1) | WO2010041149A2 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2835819A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
CN104114171A (zh) * | 2011-12-13 | 2014-10-22 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
EP3276000A3 (en) * | 2012-05-25 | 2018-02-21 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
CN102786595B (zh) * | 2012-08-03 | 2014-04-23 | 无锡傲锐东源生物科技有限公司 | 抗cd5蛋白单克隆抗体及其用途 |
CN115227826A (zh) | 2016-03-10 | 2022-10-25 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
CA3030165A1 (en) * | 2016-07-19 | 2018-01-25 | Arete Discoveries, Inc. | Biomarkers for detection and treatment of mast cell activity-associated disorders |
JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. | シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用 |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US11672092B2 (en) * | 2019-11-06 | 2023-06-06 | Steiner Enterprises | Modular electrical distribution system for vehicles |
EP4001919A1 (en) * | 2020-11-13 | 2022-05-25 | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | Predictive biomarkers of autoimmunity in patients treated with alemtuzumab |
EP4337958A1 (en) * | 2021-05-13 | 2024-03-20 | Genzyme Corporation | Novel predictive biomarkers for secondary autoimmunity after lymphocyte depleting therapy |
CA3242046A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
AU2022407454A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist in treating drug resistant her2+ cancers |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6351720B1 (en) | 1997-10-24 | 2002-02-26 | Mitsubishi Heavy Industries, Ltd. | Trolley camera position detecting apparatus |
US6045501A (en) * | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
US6315720B1 (en) * | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
JP2005501545A (ja) | 2001-09-04 | 2005-01-20 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | カスパーゼ結合タンパク質、その調製物および使用 |
ATE444363T1 (de) | 2001-11-05 | 2009-10-15 | Zymogenetics Inc | Il-21-antagonisten |
WO2003050257A2 (en) | 2001-12-06 | 2003-06-19 | University Of Florida | Targeting leukemia cells |
ES2381265T3 (es) | 2002-06-07 | 2012-05-24 | Zymogenetics, Inc. | Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos |
EP1608315A4 (en) * | 2003-03-21 | 2008-07-16 | Wyeth Corp | TREATMENT OF IMMUNOLOGICAL DISORDERS USING INTERLEUKIN-21 / INTERLEUKIN-21 RECEPTOR |
EP1670501A2 (en) * | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
RU2007102287A (ru) * | 2004-08-05 | 2008-09-10 | Вайет (Us) | Антагонисты активности рецептора интерлейкина-21 |
EP2567973B1 (en) * | 2005-11-28 | 2014-05-14 | Zymogenetics, Inc. | IL-21 antagonists |
-
2009
- 2009-10-08 PT PT171592355T patent/PT3241910T/pt unknown
- 2009-10-08 PL PL09804308T patent/PL2344677T3/pl unknown
- 2009-10-08 KR KR1020117010362A patent/KR101682730B1/ko active Application Filing
- 2009-10-08 EP EP17159235.5A patent/EP3241910B1/en active Active
- 2009-10-08 WO PCT/IB2009/007327 patent/WO2010041149A2/en active Application Filing
- 2009-10-08 PL PL17159235T patent/PL3241910T3/pl unknown
- 2009-10-08 AU AU2009302117A patent/AU2009302117B2/en active Active
- 2009-10-08 US US13/123,188 patent/US20110229470A1/en not_active Abandoned
- 2009-10-08 ES ES17159235T patent/ES2784830T3/es active Active
- 2009-10-08 MX MX2011003730A patent/MX336835B/es active IP Right Grant
- 2009-10-08 KR KR1020167033277A patent/KR101825457B1/ko active IP Right Grant
- 2009-10-08 SI SI200931691T patent/SI2344677T1/sl unknown
- 2009-10-08 BR BRPI0920546-2A patent/BRPI0920546B1/pt active IP Right Grant
- 2009-10-08 JP JP2011530591A patent/JP5856481B2/ja active Active
- 2009-10-08 CA CA2740077A patent/CA2740077A1/en not_active Withdrawn
- 2009-10-08 RU RU2011118477/10A patent/RU2563521C2/ru active
- 2009-10-08 DK DK09804308.6T patent/DK2344677T3/en active
- 2009-10-08 PT PT98043086T patent/PT2344677T/pt unknown
- 2009-10-08 EP EP09804308.6A patent/EP2344677B1/en active Active
- 2009-10-08 ES ES09804308.6T patent/ES2632213T3/es active Active
- 2009-10-08 CN CN200980149287.1A patent/CN102245783B/zh active Active
- 2009-10-08 LT LTEP09804308.6T patent/LT2344677T/lt unknown
- 2009-10-08 HU HUE09804308A patent/HUE035208T2/hu unknown
-
2011
- 2011-03-31 IL IL212069A patent/IL212069A/en active IP Right Grant
-
2014
- 2014-06-17 JP JP2014124055A patent/JP2014195462A/ja active Pending
-
2016
- 2016-02-02 US US15/013,808 patent/US10598670B2/en active Active
-
2017
- 2017-07-04 CY CY20171100709T patent/CY1119513T1/el unknown
- 2017-07-04 HR HRP20171023TT patent/HRP20171023T1/hr unknown
-
2018
- 2018-05-04 HK HK18105788.5A patent/HK1246364A1/zh unknown
-
2020
- 2020-02-25 US US16/801,009 patent/US11243211B2/en active Active
-
2022
- 2022-01-12 US US17/574,282 patent/US20220349899A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119513T1 (el) | Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης | |
CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
Apostolova et al. | Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis | |
CY1120423T1 (el) | Β7-η1 και pd-1 στη θεραπεια του καρκινωματος νεφρικων κυτταρων | |
Julayanont et al. | Montreal Cognitive Assessment Memory Index Score (MoCA‐MIS) as a Predictor of Conversion from Mild Cognitive Impairment to A lzheimer's Disease | |
CY1118377T1 (el) | Syk αναστολεις ιμιδαζοπυραζινης | |
CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
CY1117817T1 (el) | Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων | |
CY1118660T1 (el) | Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων | |
CY1113058T1 (el) | Συνδυαστικη θεραπεια για την αντιμετωπιση οφθαλμικων νεοαγγειακων διαταραχων | |
CY1115871T1 (el) | Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας | |
CY1118549T1 (el) | Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
CY1121335T1 (el) | Anti-cxcr3 αντισωματα | |
CY1116256T1 (el) | Il-17 ανταγωνιστικα αντισωματα | |
CY1117286T1 (el) | Μεσα και μεθοδοι για την αντιμετωπιση μυϊκων διαταραχων | |
CY1117155T1 (el) | Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl | |
Siskind et al. | A review of genetic counseling for Charcot Marie Tooth disease (CMT) | |
AR088827A1 (es) | Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer | |
UY29282A1 (es) | Anticuerpos humanizados que reconocen el peptido beta amiloideo | |
ATE439868T1 (de) | Targetingmittel für molekulare bilderzeugung | |
CY1118663T1 (el) | Μεθοδος αναγνωρισης κινδυνου για διαταραχη του θυρεοειδους | |
ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
CY1112288T1 (el) | Θεραπεια του καρκινου με αντισωματα κατα της il-1a | |
ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
Ouellette et al. | Predicting discharge destination with admission outcome scores in stroke patients |